Northwire Canada EditionFriday, July 10, 2026
Sign inSubscribe
Northwire
⌕
NNX 0.035 +0.0% ABX 51.92 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 22.70 +9.1% TUNG 1.74 +3.0% LGO 1.00 −3.9% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.49 +0.9% SGZ 0.045 +0.0% S 0.160 +33.3% GRSL 0.305 −4.7% DEX 0.390 +1.3% WMS 0.040 +0.0% NNX 0.035 +0.0% ABX 51.92 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 22.70 +9.1% TUNG 1.74 +3.0% LGO 1.00 −3.9% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.49 +0.9% SGZ 0.045 +0.0% S 0.160 +33.3% GRSL 0.305 −4.7% DEX 0.390 +1.3% WMS 0.040 +0.0%
Financings Neutral

DIAGNOS Announces Shares for Debt Settlement

Cash-preserving debt settlement underscores ongoing liquidity constraints ahead of critical CARA regulatory milestones.

By The Northwire Desk — AI Analysis Jun 18, 2026 · 12:00 ADK · 0.22 Diagnos Inc.
Executive Summary
  • On June 18, 2026, DIAGNOS Inc. announced it will settle two arm's-length demand loans totaling C$125,000 by issuing 625,000 common shares at C$0.20 per share.
  • The transaction is designed to preserve the company's limited cash reserves.
  • Accrued interest on the loans will be paid in cash upon settlement.
  • Issued shares carry a mandatory hold period of four months and one day.
  • Settlement is subject to TSX Venture exchange acceptance and regulatory compliance, with an anticipated date of June 25, 2026.
Material Impact
  • The C$125,000 debt settlement is a minor, routine corporate action that avoids a cash outflow, which is operationally necessary given the company's explicit going concern risk and ~$320,000 monthly burn rate.
  • Dilution is minimal, representing approximately 0.5% of the ~120.4 million shares outstanding.
  • The transaction does not alter the fundamental investment thesis, nor does it resolve the broader capital requirement explicitly flagged by management for the end of calendar 2026.
  • The market is unlikely to price this as a catalyst, as it aligns with standard liquidity management practices for pre-revenue medical AI developers.
ADK · Price
Company Overview
  • DIAGNOS Inc. develops the CARA System, a cloud-based AI platform designed to detect retinal diseases and systemic conditions through standard fundus photography.
  • The platform currently targets early detection of age-related macular degeneration (AMD) and diabetic retinopathy.
  • The company has established commercial relationships with major optical industry participants, including EssilorLuxottica and IRIS The Visual Group.
  • Management estimates an approximately C$11 billion addressable market opportunity for CARA.
  • The company has secured over C$1.0 million in federal funding to develop next-generation retinal AI algorithms in collaboration with École de Technologie Supérieure (ÉTS).
Read the original news release →

More from Diagnos Inc.

Jun 16, 2026 · 09:15

Pre-revenue medical AI developer navigating regulatory hurdles while burning through cash reserves.

Regulatory Jun 05, 2026 · 10:00

DIAGNOS Inc. Awaits Health Canada Catalyst as Cash Runway Narrows Ahead of Dilutive Financing

Regulatory Apr 08, 2026 · 12:14

Regulatory timeline update keeps CARA on track, no surprise for investors

Production / Operations Mar 05, 2026 · 18:26

Diagnos to amend convertible debenture, warrant terms

Financings Mar 05, 2026 · 15:45

DIAGNOS Announces Amendments to Convertible Debentures and Stock Warrants

Financings Feb 25, 2026 · 12:13

SEDAR Interim Financial Statements

None